These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Inhibition of NF-kappa B transcription factor by catechol derivatives.
    Author: Suzuki YJ, Packer L.
    Journal: Biochem Mol Biol Int; 1994 Feb; 32(2):299-305. PubMed ID: 8019435.
    Abstract:
    Therapeutic agents which target NF-kappa B transcription factor may be useful in the management of AIDS, cancer and inflammation. Since oxidative stress has been implicated in the signaling pathway, the use of antioxidants to inhibit NF-kappa B activation has gained attention. In the present study, we examined the effects of catechol derivatives, nitecapone and OR-1246, which have been identified to possess potent antioxidant properties, on NF-kappa B activation by monitoring its DNA binding activity. Both nitecapone and OR-1246 (10-300 microM) inhibited NF-kappa B activation induced by tumor necrosis factor-alpha in Jurkat T (acute human leukemia) cells. Nitecapone was a better inhibitor than OR-1246. The observed effects may, at least in part, be due to the ability of the two compounds to directly inhibit DNA binding activity of activated NF-kappa B. The inhibitory capability of OR-1246 on NF-kappa B DNA binding does not appear to be a sole mechanism, as it did not inhibit NF-kappa B activation induced by okadaic acid. Hence, catechol derivatives inhibit NF-kappa B transcription factor through multiple mechanisms, and nitecapone and OR-1246 may be useful as therapeutic agents targeting NF-kappa B.
    [Abstract] [Full Text] [Related] [New Search]